Pyxis Oncology, Inc. · Drugmakers

PYXS

High riskNext report: In 6 days (est.)

View price ↗

The short version

A company still losing money with shrinking sales, with high risk.

Going well

No debt reported

Watch out for

About 3 months of cash left at its current burn
Share count growing 23.4% a year (dilution)
Losing money, losses are large next to sales

Money moves

No insider buying or selling in the last 30 days
Institutions added 24% to their holdings in the quarter ending June 2026 (34 bought, 34 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$1.70+1.8% that day

Company value: $142M; Share price times all shares
Price vs sales: 10.2x; No profit over the last year, so this compares value with sales instead
Cash vs value: 13%; Cash as a share of company value

From PYXS's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Profit, Jun '26

-$25.3M

Sep '23Tap a barJun '26

Last 12 months: -$88.7M.

What the price assumes

Your guesses, our math

Move the sliders to your own view of PYXS. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth+5% a yearRecent growth not reportedProfit margin10%Not reportedP/E at the end15xMany steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$18M

Profit in 5 years$2M

Price these guesses point to$0.20-88% vs $1.70 todayAbout -35% a year, before dividends

What today's price needs: with a 10% margin and a 15x P/E, sales would have to grow about 61% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-91.4%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.Losses many times its sales
MissProfitable every yearSteady profits, not one good year.0 of 6 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$63.5M
MissShare count not growingNot diluting owners. Falling means buybacks.+88.1% in 3 years

Revenue: $13.9M; -14.2% vs prior year
Total debt: None; 0.00x equity
Current ratio: 3.41x; short-term assets / bills due
Free cash flow: -$63.5M; -458.3% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 13

EPS: -$0.40; vs -$0.30
Free cash flow: -$18.2M
Share count: +3.3%; vs a year ago

Insider rating

Last 90 days

58Mixed

GordonMD Global Investments LP grew their stake 55%

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

39/ 100

This week: 1
Normal week: 1.7
vs normal: 0.6x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady+23.9%

Institutions added 23.9% to their holdings. 34 bought, 34 sold.

Shares held by institutions34.2M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+28.1%

Cash runwayAt last year's cash burn

4 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

83M

Why high risk

Losing money, losses are large next to sales
About 4 months of cash left at its current burn
Share count growing 28.1% a year (dilution)
Revenue down 14.2% from the year before
5 offering filings in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportIn 6 days (est.)Estimated from the same quarter last year

Results filedAug 13
Results filedMay 14
Results filedMar 23
Results filedNov 3, 2025
Results filedAug 14, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Oct 9 · View filing ↗Big holder New 5%+ holder (passive)Oct 5 · View filing ↗Big holder 5%+ holder update (passive)Oct 2 · View filing ↗Big holder Offering prospectusOct 1 · View filing ↗Offering Offering prospectusSep 29 · View filing ↗Offering Offering prospectusSep 29 · View filing ↗Offering Shelf offering registrationAug 20 · View filing ↗Offering Major agreementJul 2 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

Bought$01 insider

Sold$00 insiders

Insider	Trade	Shares	Avg price	Value	Owns after	Date
GordonMD Global Investments LP10% owner	Buy	6M	$0.00	$0	16M	Oct 1Filing ↗
+55% of their holdings Held See footnote Filed jointly with 3 others Filed 1 day after